Presbyopia

Latest News

FDA accepts Orasis Pharmaceuticals' NDA for CSF-1 for treatment of presbyopia
FDA accepts Orasis Pharmaceuticals' NDA for CSF-1 for treatment of presbyopia

February 21st 2023

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

Florida State University teaming up with ophthalmology drug developer
Florida State University teaming up with ophthalmology drug developer

February 9th 2023

Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment
Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment

January 9th 2023

VEGA-1 Trial: Focusing on presbyopia
VEGA-1 Trial: Focusing on presbyopia

December 31st 2022

Ocuphire reaches license agreement for the development and commercialization of Nyxol
Ocuphire reaches license agreement for the development and commercialization of Nyxol

November 8th 2022

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.